FDA Warning Letter expands scope of FDA Form 483 The Warning Letter to Applied Therapeutics identified critical issues, specifically regarding dosing error, data integrity and protocol adherence ...
The FDA issues a warning letter to Sanofi over manufacturing violations at its Massachusetts site, citing contamination and inadequate quality controls. The agency demands a comprehensive review, ...
In a warning letter posted online late last month, the FDA scolded Viatris over a range ... The FDA’s review of the site yielded a six-observation Form 483, which the company responded to ...
The warning letter did not identify any new observations that had not already been provided in the Form 483s previously issued to the company by the FDA at the conclusion of its three inspections ...
As part of its enforcement activities, the Food and Drug Administration (FDA) sends warning letters to entities under its ...
The FDA issued a warning letter to Sanofi regarding significant manufacturing violations at its Genzyme Corporation Facility in Framingham, Mass. The letter, dated Dec. 16, 2024, and amended Jan. 15, ...
The "FDA Inspections: From Site Preparation to Response" training has been added to ResearchAndMarkets.com's offering. This is a practical, hands-on two-day seminar designed to provide pharmaceutical, ...
The medical-technology company on Monday said the warning letter relates to quality systems identified during FDA inspections at Integra facilities located in Massachusetts and New Jersey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback